Luxfer Holdings PLC (LXFR) stock analysis
Close on Nov 13, 2026Market cap $464.01MP/E 75.4Yield –
StockData Score
Prices as of Nov 13, 2026How the score works
Mixed11 of 30 checks passed
Luxfer passes 11 of the 30 checks behind our score; 2 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 2/6
- Financial health
- 6/6
- Dividend
- 2/6
What stands out
Low debt
Debt is 26.0% of shareholders' equity, under the 40% we consider low.
Interest well covered
Operating income covers interest expense 6.6 times.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 52.0% of total debt.
Low bankruptcy risk
The Altman Z-score is 3.57; above 3 is the safe zone and below 1.8 the distress zone.
What to watch
Margin of safety under 20%
The price is 90.7% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $17.34 is above our fair value estimate of $9.09.
Return on equity under 15%
Return on equity was 2.7% over the last twelve months and averaged 8.0% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 5.5%, below the 10% that usually covers the cost of capital.
Valuation0/6
P/E above its 5-year median
Luxfer's P/E of 75.4 is above its own 5-year median of 19.0.
P/E above the industry
Luxfer's P/E of 75.4 is above the Chemicals and Allied Products median of 25.2.
EV/EBITDA above its 5-year median
Luxfer's EV/EBITDA of 22.4 is above its 5-year median of 10.2.
P/B above the industry
Luxfer's price-to-book of 2.09 is above the Chemicals and Allied Products median of 1.22.
Trading above fair value
The share price of $17.34 is above our fair value estimate of $9.09.
Margin of safety under 20%
The price is 90.7% above fair value, so there is no margin of safety.
Growth1/6
Revenue growing under 10% a year
Revenue grew -3.2% a year over the last three fiscal years, short of the 10% we look for.
EPS growing under 10% a year
Diluted EPS grew -34.1% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew -56.6% over the last twelve months, against a 5-year average of -17.4% a year.
Growing slower than the industry
Revenue grew -11.8% over the last twelve months; the Chemicals and Allied Products median is 8.2%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin improving
Gross margin was 25.1% over the last twelve months, against 22.8% a year earlier.
Past performance2/6
Return on equity under 15%
Return on equity was 2.7% over the last twelve months and averaged 8.0% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 5.5%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
Luxfer's return on equity of 2.7% is above the Chemicals and Allied Products median of -0.8%.
Earnings shrank over 5 years
Net income shrank 17.4% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 1.7% over the last twelve months, against a 5-year average of 4.1%.
Net margin above the industry
Luxfer's net margin of 1.7% is above the Chemicals and Allied Products median of -0.4%.
Financial health6/6
Low debt
Debt is 26.0% of shareholders' equity, under the 40% we consider low.
Debt falling against equity
Debt to equity fell from 32.0% five years ago to 26.0%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 52.0% of total debt.
Interest well covered
Operating income covers interest expense 6.6 times.
Short-term assets cover short-term debts
Current assets are 2.47 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 3.57; above 3 is the safe zone and below 1.8 the distress zone.
Dividend2/6
Pays a dividend
Luxfer paid dividends worth 2.2% of the share price over the last twelve months.
Yield below Treasuries
The 2.2% yield is below the 4.7% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; Luxfer yields 2.2%.
Dividend stability
Fewer than five years of dividend history.
Not covered by earnings
Dividends take 221% of net income, leaving little room.
Covered by free cash flow
Dividends take 72.5% of free cash flow.
Fair value
How we estimate itOur estimate per share
$9.09
The share price is 91% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 22.1× | 19.0× | 25.2× | $5.08 | 40% |
| EV/EBITDA | 15.8× | 10.2× | 21.4× | $11.79 | 35% |
| P/B | 1.5× | 1.7× | 1.2× | $12.29 | 10% |
| Earnings power | 9.2% cost of equity | – | – | $11.36 | 15% |
| Fair value | $9.09 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 19.0
- Chemicals and Allied Products median 25.2
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $9.25M
- Value traded per 1% price move
- $42.51M
Downside
Medium risk
- Typical loss in a bad month
- 24.0%
- Volatility (annualized)
- 31%
- Sharpe ratio, 1 year
- 1.19
- Beta to the S&P 500 (5Y)
- 0.82
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.9% | -3.2% | +3.4% | -1.8% | |
| Gross profit | +4.1% | -2.1% | +2.0% | -1.5% | |
| Operating income | -20.3% | -18.8% | -3.4% | -4.5% | |
| Net income | -58.2% | -34.1% | -17.4% | – | |
| EPS, diluted | -58.8% | -34.1% | -17.2% | -7.2% | |
| Free cash flow | -35.8% | +51.1% | -8.8% | -3.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 10.7% | 11.7% | 3.5% | |
| Return on assets | 4.3% | 5.4% | 2.0% | |
| Current ratio | 2.89 | 2.31 | 1.67 | |
| Debt to equity | 0.80 | 0.32 | 0.17 | |
| Net debt to EBITDA | 2.11× | 1.24× | 0.92× | |
| Interest coverage | 5.2× | 5.7× | 7.7× | |
| Inventory turnover | – | 3.3× | 3.4× | |
| Capex to revenue | 4.0% | 2.5% | 2.0% | |
| Diluted shares | 27M | 28M | 27M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Luxfer generated $153.40M from operations and spent $140.20M on capital expenditure, dividends and share buybacks. 32% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 2.0% | 1.02× | 1.69× | 3.5% |
| FY2024 | 4.7% | 1.04× | 1.75× | 8.5% |
| FY2023 | -0.5% | 1.04× | 1.86× | -0.9% |
| FY2022 | 6.4% | 1.09× | 1.86× | 12.9% |
| FY2021 | 8.0% | 1.05× | 1.90× | 15.9% |
| FY2020 | 6.2% | 0.88× | 2.16× | 11.7% |
| FY2019 | 0.8% | 0.93× | 2.23× | 1.7% |
| FY2018 | 6.2% | 0.97× | 2.30× | 13.9% |
| FY2017 | 3.8% | 1.08× | 2.51× | 10.2% |
| FY2016 | 4.3% | 0.99× | 2.50× | 10.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$7.70M
- Cash generatingOperating cash flow above zero$34.00M
- Return on assets improvedROA up on the prior year4.9% → 2.0%
- Earnings backed by cashOperating cash flow above net income$34.00M vs $7.70M
- Less leverageLong-term debt to assets fell11.0% → 3.9%
- Better liquidityCurrent ratio rose1.88 → 1.67
- No dilutionShare count did not rise27M → 27M
- Gross margin improvedGross margin up on the prior year21.87% → 23.19%
- More efficientAsset turnover rose1.05 → 1.01
See a number that looks wrong?